Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder

World Journal of Biological Psychiatry

Volumn 11, Issue 1, 2010, Pages 36-44

  Kasper, Siegfried ^a   Montgomery, Stuart A ^b   Möller, Hans Jürgen ^c   Van Oers, Helga J ^d   Jan Schutte, Albert ^e   Vrijland, Peter ^d   Van Der Meulen, Egbert A ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d NV ORGANON   (Netherlands)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Major Depressive Disorder; Mirtazapine; Placebo controlled studies; Risk; Suicidal behaviour

Indexed keywords

AMITRIPTYLINE; DESIPRAMINE; FLUOXETINE; MIRTAZAPINE; PLACEBO; TRAZODONE;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE TITRATION; FEMALE; HAMILTON SCALE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; RISK ASSESSMENT; SUICIDAL BEHAVIOR; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIANSERIN; PLACEBO EFFECT; SEVERITY OF ILLNESS INDEX; SUICIDE, ATTEMPTED;

EID: 76649098027     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970701691503     Document Type: Article

References (42)

1. Angst J, Angst F, Gerber-Werder R, Gamma A 2005. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res 9:279-300.
2. Bremner JD 1995. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 56:519-525.
3. Claghorn JL, Lesem MD 1995. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 34:165-171.
4. Dubicka B, Hadley S, Roberts C 2006. Suicidal behaviour in youths with depression treated with new-generation antidepres-sants: Meta-analysis. Br J Psychiatry 189:393-398.
5. Ferguson D, Doucette S, Cranley Glass K, et al. 2005. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. Br Med J 330:396.
6. Frey R, Schreinzer D, Stimpf T, Vycudilik W, Berzlanovich A, Kasper S 2000. Suicide by antidepressant intoxication identi-fed at autopsy in Vienna from 1991-1997: the favourable consequences of the increasing use of SSRIs. Eur Neuropsy-chopharmacol 10:133-142.
7. Frey R, Schreinzer D, Stimpf T, Vycudilik W, Berzlanovich A, Kasper S 2002. [Fatal poisonings with antidepressive drugs and neuroleptics. Analysis of a correlation with prescriptions in Vienna 1991 to 1997]. Nervenarzt. 73:629-636. [In German.] GSK Dear Healthcare Professional Letter, accessed January 2006; [at: http://www.fda.gov/medwatch/safety/2006/paroxetine DHCPMay06.pdf].
8. Gunnell D, Saperia J, Ashby D 2005. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. Br Med J 330:385.
9. Guze SB, Robins E 1970. Suicide and primary affective disorders. Br J Psychiatry 117:437-438.
10. Halikas JA 1995. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 10:(Suppl 2):S125-133.
11. Hamilton M 1960. A rating scale for depression. J Neurol Neuro-surg Psychiatry 23:56-62.
12. Hammad TA, Laughren T, Racoosin J 2006a. Suicidality in pedi-atric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339.
13. Hammad TA, Laughren TP, Racoosin JA 2006b. Suicide rates in short-term randomized controlled trials of newer antidepres-sants. J Clin Psychopharmacol 26:203-207.
14. Isacsson G 2000. Suicide prevention-a medical breakthrough? Acta Psychiatr Scand 102:113-117.
15. Isacsson G, Rich CL 2005. Antidepressant drug use and suicide prevention. Int Rev Psychiatry 17:153-162.
16. Isacsson G, Holmgren P, Ahlner J 2005. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psy-chiatr Scand 111:286-290.
17. Jacobson AF, Dominguez RA, Goldstein B, Gandara J de la 1990. Comparison of Org 3770 and amitriptyline in depressed outpatients. J Clin Pharmacol 30:851.
18. Jick H, Kaye JA, Jick SS 2004. Antidepressants and the risk of suicidal behaviors. J Am Med Assoc 292:338-1243
19. Kasper S, Schindler S, Neumeister A 1996. Risk of suicide in depression and its implication for psychopharmacological treatment. Int Clin Psychopharmacol 11:71-79.
20. Khan A, Khan S, Kolts R, Brown WA 2003. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 160:790-792.
21. Khan A, Khan SR, Leventhal RM, Brown WA 2001. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsycho-pharmacol 4:113-118. (Pubitemid 32587377)
22. Khan A, Warner HA, Brown WA 2000. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 7:311-316.
23. Khan MC 1995. A randomised, double-blind, placebo-controlled, 5-weeks' study of Org 3770 (mirtazapine) in major depression. Hum Psychopharmacol 10:(Suppl 2):S119-124.
24. Liang KY, Zeger SL 1986. Longitudinal data analysis using generalised linear models. Biometrika 73:13-22.
25. Ludwig J, Marcotte DE 2005. Anti-depressants, suicide, and drug regulation. J Policy Anal Manage 24:249-272.
26. Möller HJ 2006a. Evidence for benefcial effects of antidepres-sants on suicidality in depressive patients: a systematic review. Eur Arch Psychiatry Clin Neurosci 256:329-343.
27. Möller HJ 2006b. Is there evidence for negative effects of antide-pressants on suicidality in depressive patients? A systematic review. Eur Arch Psychiatry Clin Neurosci 256:476-496.
28. Montgomery SA, Åsberg M 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
29. Posner K, Oquendo MA, Gould M, Stanley B, Davies M 2007. Columbia classifcation algorithm of suicide assessment (C-CASA): Classifcation of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043.
30. Reseland S, Bray I, Gunnell D 2006. Relationship between antidepressant sales and secular trends in suicide rates in the Nordic countries. Br J Psychiatry 188:354-358.
31. Rihmer Z 2004. Decreasing national suicide rates-fact or fction?. World J Biol Psychiatry 5:55-56.
32. Rhimer Z, Rhimer A, Isacsson G 2005. Suicide and antidepres-sants sales. Br J Psychiatry 186:445-446.
33. Simon GE, Savarino J, Operskalski B, Wang PS 2006. Suicide risk during antidepressant treatment. Am J Psychiatry 163:41-47.
34. Smith WT, Glaudin V, Panagides J, Gilvary E 1990. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 26:191-196.
35. Statham DJ, Heath AC, Madden PA, et al. 1998. Suicidal behaviour: an epidemiological and genetic study. Psychol Med 28: 839-855.
36. Storosum JG, van Zwieten BJ, van den Brink W, Gersons BP, Broekmans AW 2001. Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 158:1271-1275.
37. Thompson C 2002. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 17:(Suppl 1): S27-32
38. Vanderburg D, Batzar E, Fogel I, Kremer CME 2006. Possibly suicide reated adverse events in placebo-controlled short-term studies of sertraline in adult patients. Annual Meeting of the American Psychiatric Association, May 19-26, Toronto CA. Poster No. 867.
39. Vartiainen H, Leinonen E 1994. Double-blind study of mirtaza-pine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 4:145-150. (Pubitemid 24199864)
40. Vuorilehto MS, Melartin TK, Isometsa ET 2006. Suicidal behaviour among primary-care patients with depressive disorders. Psychol Med 36:203-210.
41. Wagner S, Clifford H 1982. Simpson's paradox in real life. Am Statistician 36:46-48.
42. Witchen HU, Kessler RC, Beesdo K, Krause P, Hofer M, Hoyer J 2002. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63:(Suppl 8):24-34.